Weight loss in Parkinson's disease: A retrospective comparison between oral medication and device-assisted therapies.

Autor: Umemoto G; Swallowing Disorders Center, Fukuoka University Hospital, Fukuoka, Japan; Department of Neurology, Neuro-Muscular Center, NHO Omuta National Hospital, Fukuoka, Japan. Electronic address: george@fukuoka-u.ac.jp., Fujioka S; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Iwashita Y; Swallowing Disorders Center, Fukuoka University Hospital, Fukuoka, Japan., Dotsu Y; Swallowing Disorders Center, Fukuoka University Hospital, Fukuoka, Japan., Noda M; Department of Clinical Nutrition, Fukuoka University Hospital, Fukuoka, Japan., Tsuboi Y; Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2024 Jan; Vol. 236, pp. 108105. Date of Electronic Publication: 2023 Dec 26.
DOI: 10.1016/j.clineuro.2023.108105
Abstrakt: Objective: Weight loss (WL) is the most common symptom among patients with Parkinson's disease (PD) and has been reported to start several years before the diagnosis of PD. The relationship between WL and PD treatment is complex. This study aimed to characterize the impact of PD treatment on WL and find clues to establish the administration of nutrition for patients with PD.
Materials and Methods: Eighty-two patients with PD (mean age, 58.4 ± 10.2 years; mean Hoehn and Yahr stage, 3.2 ± 0.7) were recruited. Their treatments included deep brain stimulation (DBS) therapy (n = 34), levodopa/carbidopa intestinal gel (LCIG) therapy (n = 13), and oral medication alone (n = 35). Based on the medical records, the age of onset, disease duration, treatment options, videofluoroscopic dysphagia scale, blood test results, and weight change were collected.
Results: The median WL per year and rate of WL were -1.0 ± 2.8 kg and -1.9 ± 4.7 %, respectively. Most patients (93 %) were classified into normal nutrition and mild malnutrition groups by their CONUT scores. The median WL of the DBS group was significantly lower than that of the oral medication alone group (p < 0.01). The rate of WL showed a significant negative correlation with the age of onset (rho = -0.328, p = 0.003), but showed a significant positive correlation with the disease duration (rho = 0.231, p = 0.04).
Conclusion: These results highlighted WL in the early stages of PD and suggested the need for adequate monitoring for patients undergoing device-aided therapy as well as oral medicine-treated patients with greater WL.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: